SUMMARY OF FDA APPROVED INDICATIONS | |||
Indication | Fragmin | Lovenox | Arixtra |
Prophylaxis of DVT (deep vein thrombosis) that may lead to PE (pulmonary embolism) | |||
| X | X | X |
| X | X | X |
| * | X | X |
| X | X | |
| |||
| * | * | |
| * | * | |
| * | * | X |
| |||
| * | * | |
| * | * | |
| * | * | |
| * | * | * |
| * | * | |
Treatment of acute DVT | |||
Treatment of acute DVT with warfarin | X | ||
Treatment of VTE (venous thromboembolism) with warfarin | * | ||
Treatment of acute PE with warfarin | X | ||
Extended treatment of symptomatic VTE in patients with cancer | X | ||
Prophylaxis of ischemic complications in unstable angina and non-Q-wave MI (myocardial infarction) | X | X | * |
Acute ST-segment elevated myocardial infarction (STEMI) | X | * | |
Percutaneous angioplasty, acute coronary syndrome | * | * | * |
Anticoagulation for dialysis | * |